Catalina Capital Group LLC Buys 169 Shares of Boston Scientific Co. (NYSE:BSX)

Catalina Capital Group LLC grew its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 3.1% in the 2nd quarter, Holdings Channel.com reports. The fund owned 5,578 shares of the medical equipment provider’s stock after purchasing an additional 169 shares during the period. Catalina Capital Group LLC’s holdings in Boston Scientific were worth $430,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Boston Scientific by 1.6% during the first quarter. Vanguard Group Inc. now owns 127,437,884 shares of the medical equipment provider’s stock valued at $8,728,221,000 after acquiring an additional 1,988,082 shares during the last quarter. Primecap Management Co. CA increased its position in shares of Boston Scientific by 1.5% during the fourth quarter. Primecap Management Co. CA now owns 37,905,659 shares of the medical equipment provider’s stock worth $2,191,326,000 after buying an additional 550,490 shares during the period. Norges Bank acquired a new stake in shares of Boston Scientific during the fourth quarter worth $930,626,000. Capital World Investors increased its position in shares of Boston Scientific by 69.9% during the first quarter. Capital World Investors now owns 16,008,085 shares of the medical equipment provider’s stock worth $1,096,394,000 after buying an additional 6,588,256 shares during the period. Finally, Putnam Investments LLC increased its position in shares of Boston Scientific by 110.5% during the fourth quarter. Putnam Investments LLC now owns 13,067,570 shares of the medical equipment provider’s stock worth $755,436,000 after buying an additional 6,859,280 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 0.5 %

Shares of NYSE:BSX traded down $0.41 during midday trading on Friday, hitting $79.17. 4,006,157 shares of the company’s stock were exchanged, compared to its average volume of 6,148,074. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14. The stock has a 50 day moving average price of $76.59 and a 200-day moving average price of $72.40. The company has a market cap of $116.15 billion, a PE ratio of 66.53, a price-to-earnings-growth ratio of 2.49 and a beta of 0.78. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $79.92.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.80%. The business had revenue of $4.12 billion for the quarter, compared to analysts’ expectations of $4.02 billion. During the same period in the previous year, the company earned $0.53 earnings per share. The firm’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Morgan Stanley increased their price objective on shares of Boston Scientific from $79.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, July 15th. Truist Financial increased their price objective on shares of Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Canaccord Genuity Group increased their price objective on shares of Boston Scientific from $83.00 to $88.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Argus lifted their price target on shares of Boston Scientific from $80.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, May 28th. Finally, The Goldman Sachs Group started coverage on shares of Boston Scientific in a research note on Thursday, May 30th. They issued a “buy” rating and a $90.00 price target for the company. Two analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $85.24.

Insider Buying and Selling

In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $74.12, for a total transaction of $517,579.96. Following the transaction, the executive vice president now directly owns 40,188 shares in the company, valued at $2,978,734.56. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $74.12, for a total transaction of $517,579.96. Following the transaction, the executive vice president now directly owns 40,188 shares in the company, valued at $2,978,734.56. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 14,011 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $75.34, for a total transaction of $1,055,588.74. Following the completion of the transaction, the executive vice president now owns 20,197 shares in the company, valued at $1,521,641.98. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 34,960 shares of company stock worth $2,638,984. 0.50% of the stock is owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.